Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 4Genitourinary 3Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Classical hematology 1Breast 1

Conditions

Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × ARQ 197 × Sarcoma × Clear all
NCT00557609 2013-02-08

Phase 2 Study in Patients With MiT Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 2 Completed
47 enrolled
GenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡